MANGOCEUTICALS, INC.
No enriched coverage for $MGRX in the last 7 days.
No SEC Form 4 filings for $MGRX in the last 30 days.
See all $MGRX insider activity →Mangoceuticals (MGRX) shares rose 31.9% pre-open to $0.5612 after its merger partner, Nuclea Energy, said it reached a regulatory and siting milestone via a memorandum of understanding to locate the Morpheus microreactor at Utah’s San Rafael Energy Lab. The MOU supports a planned business combination that remains subject to approvals, with earnings expected around Aug. 13.
Mangoceuticals (MGRX) shares rose more than 49% after hours after the company said it signed an MOU with Nuclea Energy to explore siting a nuclear test reactor at Utah’s San Rafael Energy Lab to support Nuclea’s Morpheus microreactor. Mangoceuticals and Nuclea have a July 30 business combination agreement, pending approvals. MGRX received a 180-day Nasdaq bid-price extension to Feb. 1, 2027.
Mangoceuticals (MGRX) signed a definitive deal to combine with Nuclea Energy to advance Nuclea’s Morpheus nuclear microreactor to public markets. Nuclea shareholders will receive exchangeable shares in a new Mangoceuticals subsidiary, exchangeable one-for-one into MGRX common stock, subject to Nasdaq limits. MGRX closed at $0.29, down 46.88%, after a $0.16 to $2.75 52-week range.
Recent MGRX coverage spans mergers & acquisitions, corporate actions and financial news.
The stock’s move is tied to incremental deal credibility and a tangible nuclear microreactor proof-of-concept, ahead of an Aug. 13 earnings window.
The stock jump is driven by merger-related headlines plus a Nasdaq compliance extension, but the deal still requires approvals.
The announced definitive deal is a direct catalyst for MGRX, with near-term trading driven by deal mechanics, exchange ratio, and regulatory/commercial roadmap expectations.
The disclosed definitive deal terms are the primary driver of the after-hours repricing, with approval risk and dilution mechanics in focus.
Deal headline is bullish for MGRX optionality to advanced nuclear, but near-term trading hinges on approvals and deal structure limits.
alphai scores every news story that mentions MGRX with an AI model for sentiment and relevance, and aggregates insider trades from MANGOCEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Mangoceuticals (MGRX) shares rose 31.9% pre-open to $0.5612 after its merger partner, Nuclea Energy, said it reached a regulatory and siting milestone via a memorandum of understanding to locate the Morpheus microreactor at Utah’s San Rafael Energy Lab. The MOU supports a planned business combination that remains subject to approvals, with earnings expected around Aug. 13.
3 min readMangoceuticals (MGRX) shares rose more than 49% after hours after the company said it signed an MOU with Nuclea Energy to explore siting a nuclear test reactor at Utah’s San Rafael Energy Lab to support Nuclea’s Morpheus microreactor. Mangoceuticals and Nuclea have a July 30 business combination agreement, pending approvals. MGRX received a 180-day Nasdaq bid-price extension to Feb. 1, 2027.
4 min readMangoceuticals (MGRX) signed a definitive deal to combine with Nuclea Energy to advance Nuclea’s Morpheus nuclear microreactor to public markets. Nuclea shareholders will receive exchangeable shares in a new Mangoceuticals subsidiary, exchangeable one-for-one into MGRX common stock, subject to Nasdaq limits. MGRX closed at $0.29, down 46.88%, after a $0.16 to $2.75 52-week range.
4 min readMangoceuticals, Inc. (NASDAQ:MGRX) shares are trending on Thursday night. Shares of the public health and wellness company jumped 137.77% to $0.70 in after-hours trading on Thursday following the announcement of a definitive business combination with Nuclea Energy Inc., a developer of the Morpheus lead-cooled microreactor.
4 min readMangoceuticals (NASDAQ: MGRX) said it signed a definitive business combination agreement with Nuclea Energy to take Nuclea’s Morpheus lead-cooled microreactor public. A new Mangoceuticals subsidiary will amalgamate with Nuclea, with Nuclea shareholders receiving exchangeable shares. Closing is subject to Mangoceuticals and Nasdaq approvals, with rights capped at 19.99% until then.
4 min readNuclea Energy Inc. said it signed a definitive business combination agreement with Mangoceuticals, Inc. (NASDAQ: MGRX) to pursue a Nasdaq public listing for Nuclea. Nuclea shareholders will receive exchangeable shares tied to Mangoceuticals common stock, with former Nuclea holders owning about 96% and Mangoceuticals holders about 4% post-closing, subject to approvals and a 19.99% Nasdaq cap.
4 min readMANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ex2-1.htm EX-2.1 Exhibit 2.1 Execution Version BUSINESS COMBINATION AGREEMENT THIS BUSINESS COMBINATION AGREEMENT (this “ Agreement ”) is made as of July 29, 2026 (the “ Execution Date ”), AMONG: MANGOCEUTICALS, INC. , a corporation incorporated under the Laws of the Sta
6 min readMANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SUBSCRIPTION AGREEMENT IN MANGOCEUTICALS, INC. A. Subscription . This Agreement has been executed by __________________________, a/an ( Individual/Corporation/LLC/Trust/Partnership ) , residing and/or having a principal place of business
4 min readMangoceuticals Inc. reported a Q1 2026 net loss of $3.4 million on revenues of $67,864, down from the prior year, with significant spending on operations and stock-based compensation. The company's cash and cash equivalents dwindled to $174,562, highlighting severe liquidity concerns and the need for new financing. Intangible assets, primarily patents and licenses, comprise the majority of the company's total assets, while liabilities remain relatively modest.
3 min readMangoceuticals, Inc. (NASDAQ:MGRX) shares are trading higher due to the early success of its new all-inclusive injectable Testosterone Replacement Therapy (TRT) treatment program. The company reported a 336% increase in month-over-month sales for its TRT program since mid-December and a 54% reduction in customer acquisition costs. This $99-per-month program, delivered via telehealth, is expected to be Mangoceuticals' primary growth driver.
4 min read
